The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20140307: JDS Uniphase Corporation; Thoma Bravo Fund X, L.P.
20140335: Clayton, Dubilier & Rice Fund IX, L.P.; PharMEDium Healthcare Corporation
20140339: Post Holdings, Inc.; Tricor Pacific Capital Partners (Fund IV), LP
20140346: Audax Private Equity Fund IV AIV, L.P.; Evangelos P. Proimos Living Trust UAD 11/19/2003
16 CFR Part 305: Energy and Water Use Labeling for Consumer Products Under the Energy Labeling Rule; Proposed Conforming Amendments to Require a New DOE Test Procedure for Televisions and Establish Data Reporting Requirements
20140310: Calpine Corporation; Wayzata Opportunities Fund II, L.P.
20140308: KKR Asian Fund II L.P. AIV, a To-Be-Formed Entity; Panasonic Corporation
20140309: The WhiteWave Foods Company; Canada Pension Plan Investment Board
1312008 Informal Interpretation
Mylan Inc., Agila Specialties Global Pte.Limited, Agila Specialties Private Limited, and Strides Arcolab Limited, In the Matter of
Under a settlement with th FTC, Mylan, Inc., and Agila Specialties Global Pte. Ltd and Agila Specialties Pvt. Ltd. (collectively, Agila) divested 11 generic injectable drugs as a condition of allowing Mylan’s proposed acquisition of Agila from Strides Arcolab Ltd. (Strides). According to the complaint, in each of these 11 markets, Mylan and Agila are two of only a limited number of current or likely future competitors. The number of suppliers in generic pharmaceutical markets matters because prices generally decrease as the number of competing generic suppliers increases. In addition, the injectable generic products of concern are highly susceptible to supply disruptions caused by the inherent difficulties of producing sterile liquid drugs.